[S-18-1] Preclinical biomarkers of Alzheimer's disease

Akinori Nakamura (Department of Clinical and Experimental Neuroimaging, National Center for Geriatrics and Gerontology, Japan)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.

[S-18-2] Preclinical pathogenesis of Parkinson's disease

Noriko Nishikawa (National Center of Neurology and Psychiatry, Japan)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.

[S-18-3] Preclinical pathogenesis and biomarkers of motor neuron diseases

Masahisa Katsuno (Department of Neurology, Nagoya University Graduate School of Medicine, Japan)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.

[S-18-4] RISCA: preclinical cohort of spinocerebellar ataxia

Thomas Klockgether (Department of Neurology, University of Bonn, Germany)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.